Brief: Modus Therapeutics Updates On Sevuparin Phase 1B Clinical Trial Timelines
25/05/2022 17:01
May 25 (Reuters) - Modus Therapeutics Holding AB MODTX.ST :
* MODUS THERAPEUTICS UPDATES ON SEVUPARIN PHASE 1B CLINICAL
TRIAL
TIMELINES
* MODUS THERAPEUTICS HOLDING- ONGOING EFFECTS OF COVID-19
PANDEMIC
THROUGHOUT SPRING SLOWED DOWN ENROLMENT FOR PHASE 1B TRIAL,
CAUSING DELAY TO TIMELINES
* SAYS COMPANY NOW EXPECTS TO FINALIZE RECRUITMENT BY END Q3
Source text for Eikon: ID:nWkrDMCYZ
Further company coverage: MODTX.ST
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Modus Therapeutics Holding AB
See all newsBrief: Modus Therapeutics Temporarily Pauses Enrollment In Phase IIa Study Of Sevuparin In CKD With Anemia
Brief: Modus Gets SEK 0.13 Mln Through Exercise Of Warrants
Brief: Modus Therapeutics Resolves On Directed Share Issue Of 20 Million Shares
Sweden's Modus Therapeutics narrows Q2 net loss, extends financing
Brief: Modus Therapeutics Q2 Net Income SEK -4.645 Million